Evofem Biosciences (NASDAQ: EVFM) is one of 548 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Evofem Biosciences to related businesses based on the strength of its institutional ownership, analyst recommendations, dividends, profitability, valuation, earnings and risk.
This table compares Evofem Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Evofem Biosciences Competitors||-1,760.46%||-120.17%||-28.09%|
73.1% of Evofem Biosciences shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.4% of Evofem Biosciences shares are held by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Evofem Biosciences and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Evofem Biosciences||N/A||-$125.71 million||-0.71|
|Evofem Biosciences Competitors||$2.15 billion||$228.73 million||-3.52|
Evofem Biosciences’ competitors have higher revenue and earnings than Evofem Biosciences. Evofem Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Evofem Biosciences has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Evofem Biosciences’ competitors have a beta of 1.38, meaning that their average stock price is 38% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Evofem Biosciences and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Evofem Biosciences Competitors||4546||13020||27669||994||2.54|
Evofem Biosciences presently has a consensus target price of $11.10, suggesting a potential upside of 171.39%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.49%. Given Evofem Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Evofem Biosciences is more favorable than its competitors.
Evofem Biosciences beats its competitors on 8 of the 13 factors compared.
About Evofem Biosciences
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.